Ventyx Biosciences has reported encouraging top-line outcomes from its single-centre Phase IIa trial of the central nervous ...

Detailed price information for Ventyx Biosciences Inc (VTYX-Q) from The Globe and Mail including charting and trades.

In the last year, multiple insiders have substantially increased their holdings of Ventyx Biosciences, Inc. (NASDAQ:VTYX) stock, indicating that insiders' optimism about the company's prospects has ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...

Ventyx Biosciences disclosed positive top-line results from its Phase 2a study of VTX3232 in patients with early-stage Parkinson's disease.

Detailed price information for Ventyx Biosciences Inc (VTYX-Q) from The Globe and Mail including charting and trades.

Jefferies analysts said on Tuesday that Ventyx could leverage its mid-stage data for VTX3232 to position the oral drug candidate as a treatment for other neurodegenerative diseases, including ...

No acute changes in exploratory PET imaging were observed, consistent with a relatively short, 28-day study Ventyx intends to present the complete dataset at a future medical meeting and to ...

Ventyx Biosciences announced positive results from its Phase 2a study of VTX3232, an NLRP3 inhibitor, demonstrating safety and tolerability in patients with early-stage Parkinson's disease.

Investing.com -- Ventyx Biosciences (NASDAQ: VTYX) stock was unchanged following the announcement of top-line data from its Phase 2a safety and biomarker trial evaluating VTX3232 in patients with ...